Compare Lennar Corporation (LEN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs TransMedics Group Inc — how do they compare? Lennar Corporation trades at $87.48 (market cap $21.05B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Lennar Corporation is far larger — about 6.8× TransMedics Group Inc's market cap, and Lennar Corporation pays a 2.28% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| LEN | TMDX | |
|---|---|---|
Market Cap | $21.05B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $142.40 | $150.42 |
52-Week Low | $81.84 | $61.99 |
Enterprise Value | $24.93B | $3.49B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $85.70, up 0.12% today, with a neutral technical signal and bullish moving averages. The stock shows mixed earnings performance, missing EPS estimates in three of the last four quarters, while maintaining a modest dividend. Valuation ratios appear reasonable with a P/E of 13.72 and P/B below 1. Recent news highlights price volatility and analyst scrutiny amid housing market pressures.
LEN presents a cautious opportunity with undervalued metrics but faces headwinds from declining profitability and housing affordability challenges. Analyst consensus leans buy (46%) with a $84.30 target, near current price. Key risks include earnings misses, rising mortgage rates, and competitive threats from disruptors like Boxabl. Upside depends on execution improvement and market stabilization.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
